Equities research analysts expect Endo International PLC (NASDAQ:ENDP) (TSE:ENL) to report earnings per share (EPS) of $0.57 for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for Endo International’s earnings. The highest EPS estimate is $0.59 and the lowest is $0.55. Endo International reported earnings of $0.75 per share during the same quarter last year, which would indicate a negative year over year growth rate of 24%. The company is scheduled to report its next earnings results on Thursday, February 27th.
According to Zacks, analysts expect that Endo International will report full-year earnings of $2.20 per share for the current fiscal year, with EPS estimates ranging from $2.09 to $2.23. For the next year, analysts anticipate that the firm will post earnings of $2.32 per share, with EPS estimates ranging from $1.82 to $2.58. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.60 EPS for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.07. The firm had revenue of $729.00 million for the quarter, compared to analyst estimates of $709.01 million. Endo International had a negative return on equity of 99.08% and a negative net margin of 16.89%. The company’s revenue was down 2.1% on a year-over-year basis. During the same quarter last year, the company earned $0.71 EPS.
Shares of ENDP traded down $0.07 during trading hours on Monday, hitting $4.63. 5,266,669 shares of the company were exchanged, compared to its average volume of 7,055,606. Endo International has a fifty-two week low of $1.97 and a fifty-two week high of $12.49. The company has a market cap of $995.55 million, a price-to-earnings ratio of 1.83 and a beta of 1.43. The firm’s fifty day moving average is $4.65 and its 200 day moving average is $3.91.
In other news, Director Roger H. Kimmel sold 25,000 shares of Endo International stock in a transaction on Monday, September 16th. The stock was sold at an average price of $4.09, for a total value of $102,250.00. Following the transaction, the director now owns 123,309 shares in the company, valued at approximately $504,333.81. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.50% of the company’s stock.
Several hedge funds have recently bought and sold shares of ENDP. Paloma Partners Management Co bought a new stake in shares of Endo International during the 2nd quarter valued at approximately $98,000. Meeder Asset Management Inc. lifted its stake in Endo International by 47.1% in the 2nd quarter. Meeder Asset Management Inc. now owns 37,887 shares of the company’s stock valued at $156,000 after purchasing an additional 12,127 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in Endo International by 14.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 50,690 shares of the company’s stock valued at $163,000 after purchasing an additional 6,434 shares during the last quarter. Commonwealth Bank of Australia boosted its position in Endo International by 41.6% in the second quarter. Commonwealth Bank of Australia now owns 66,400 shares of the company’s stock valued at $273,000 after buying an additional 19,500 shares in the last quarter. Finally, Hunter Associates Investment Management LLC boosted its position in Endo International by 37.4% in the second quarter. Hunter Associates Investment Management LLC now owns 94,075 shares of the company’s stock valued at $388,000 after buying an additional 25,625 shares in the last quarter. 97.05% of the stock is owned by hedge funds and other institutional investors.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Story: Federal Reserve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.